Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/15/2024 (updated 5/23/2024)
The 2024 RCORP Data Coordinator meeting series began in May 2024, hosted by RCORP-Evaluation (Customer Value Partners), in partnership with RCORP-TA (JBS International). The purpose of this meeting series is to present a deep dive into all aspects of PIMS data collection with an overview of data requirements, data collection, and addressing common data collection challenges with hands-on best practices. This series is geared towards Data Coordinators; however, anyone involved in RCORP grant data collection is welcome to join. You can find slides, recordings, and materials from the meetings linked below.
Posted 2/14/2023 (updated 4/15/2024)
The RCORP Data Coordinator meeting series began in July 2022, hosted by RCORP-Evaluation in partnership with RCORP-TA. These meetings provide an opportunity for the JBS RCORP team to work with Data Coordinators and other consortium staff to address topics impacting data quality, reporting and utilization. Discussion in these meetings helps to inform additional webinar sessions and resources, developed to meet grantee needs.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of RCORP’s ability to impact service capacity, access, and health status within our rural communities.
Posted 4/26/2022 (updated 3/27/2024)
Overview of the jail-based Medication Assisted Treatment program within the Adult Detention Center in Fairfax County, Virginia.
Posted 3/23/2022 (updated 3/27/2024)
The JBS evaluation team will review and provide guidance on the PIMS measures that are most problematic for grantees and the new PIMS measures that are pending OMB approval. They will also highlight ways that consortiums can use their data dashboards to highlight successes and areas for improvement as they work to obtain funding and motivate and engage stakeholders.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).